McKesson partners with TrakCel aiming to address the supply chain challenges of cell and gene therapy developers in late stages of development or approaching commercialization.
Four pharma companies are providing half of the investment required for ‘world’s largest genetics project’, in return for access to the genomic data generated.
South Korea looks to accelerate review timelines and study start-up with a new five-year plan that will benefit biotechs looking for locations outside the US to ‘ramp up’ clinical development programs, says CRO.
The seventh #NLSDays event saw the latest trends in fields including ATMP, clinical evolution, and R&D technologies, find their audience in Scandinavia.
Noile-Immune signs its second high profile agreement, the latest with Adaptimmune to combine the companies’ technology in pre-clinical studies for the treatment of cancer.
Already in 2019, there have been a number of deals to pick up vector and plasmid manufacturers, such acquisitions are a sign of a rapidly developing market, one report suggests.
Atelerix to work on the development of gel stabilisation technologies enabling room temperature storage of Rexgenero’s cell therapy candidate, under an Innovate UK grant.
UK government invests further in businesses manufacturing advanced therapies, opening a fund for companies working on technology to improve commercial production.
Themis obtains an exclusive licence from Merck to develop vaccine candidates with an undisclosed indication, using its measles virus vector-based platform.
Researchers discover scorpion toxin that triggers pain through a previously unknown pathway, potentially opening up new avenues of investigation for treating chronic pain.
Once a neglected area of pharma research, companies are now investing heavily after several major commercial successes and with promising new avenues of research progressing.
The US HSS will provide funding to Merck for a year’s supply of its investigational Ebola vaccine for use in DR Congo to combat the repeated outbreaks of the virus.
The global market for regenerative medicines raised $4.8bn in the first half of 2019; a slowdown compared to the same period of 2018, though the sector is poised for additional growth, says ARM CEO.
Compared to June 2018, the biomedical manufacturing output in Singapore city rises by 5% this month, concurrently boosting the country’s overall pharmaceuticals output growth.
New data on the genetic biomarkers impacting the development of cancer treatments has been released creating the largest publicly accessible dataset of its kind.
Lonza extends its deal with Omeros for the commercial manufacture of a treatment for thrombotic microangiopathy, ahead of filing with the US FDA and the EMA.
Celltrion has partnered with Nan Fung Group to create Vcell Healthcare, which will manufacture and commercialize three of Celltrion’s biosimilar products in China.
The summer months are traditionally slow on movements across the industry, but July saw a number of manufacturing partnership deals take place as companies look ahead to product commercialization.
As we have entered the summer, companies have taken to refreshing their leadership positions, including at companies such as Gilead, Alnylam, and Maze Therapeutics.
J&J will test a vaccine candidate for HIV prevention in 3,800 men across the US and Europe, at the same time as ViiV releases positive comparative data on its HIV treatment.
Vaccine research is still quite ‘empirical’ and there is a long way until it is turned into a rational, predictable modality, suggests director at the Bill and Melinda Gates Foundation.
The major trend so far in 2019 is the willingness to deploy capital to expand services in the cell and gene therapy sector, and we outline the five most significant deals thus far.
BMS’ capture of Celgene caught much attention, due to the size and scale of the acqusition, but rival companies have taken the chance to snap up employees that have left after the deal.
GSK signs partnership deal with the University of California to advance genomic research, which sees the creation of a lab and funding for five years of research.
Genmab agrees deal with Janssen to develop a next-generation mAb product in oncology, which looks to build on the commercial success of the companies’ partnership on Darzalex.
Vertex agrees to acquire Exonics and to expand its collaboration with CRISPR Therapeutics, which sees it invest $420m in upfront payments to develop its position in gene therapy.
Servier to work with Yposeski for the production of lentiviral vectors, as the former works to develop allogenic CAR-T cell technology for hematological therapies.
Amgen and Takeda will join fellow big pharma companies Sanofi, GSK, and Janssen, in working to progress Feldan’s intracellular drug delivery technology.
Bluebird has received EU conditional marketing approval for patients with transfusion-dependent β-thalassemia, becoming the first treatment from its pipeline to receive approval.